Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside

Oncotarget. 2016 Jul 5;7(27):41172-41185. doi: 10.18632/oncotarget.9226.


There are still unmet medical needs in the treatment of glioblastoma, the most common and the most aggressive glioma of all brain tumors. Here, we found that O-acetyl GD2 is expressed in surgically resected human glioblastoma tissue. In addition, we demonstrated that 8B6 monoclonal antibody specific for O-acetylat GD2 could effectively inhibit glioblastoma cell proliferation in vitro and in vivo. Taken together, these results indicate that O-acetylated GD2 represents a novel antigen for immunotherapeutic-based treatment of high-grade gliomas.

Keywords: ganglioside; glioblastoma; immunotherapy.

MeSH terms

  • Adult
  • Aged
  • Animals
  • Antibodies, Monoclonal / therapeutic use*
  • Apoptosis / immunology
  • Cancer Vaccines / therapeutic use*
  • Cell Line, Tumor
  • Female
  • Gangliosides / immunology*
  • Gangliosides / metabolism
  • Glioblastoma / immunology
  • Glioblastoma / metabolism
  • Glioblastoma / therapy*
  • Humans
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mice, Nude
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Xenograft Model Antitumor Assays


  • Antibodies, Monoclonal
  • Cancer Vaccines
  • Gangliosides
  • ganglioside, GD2